Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lee, Seung J ^a   Krauthauser, Candice ^a   Maduskuie, Victoria ^a   Fawcett, Paul T ^a   Olson, James M ^b   Rajasekaran, Sigrid A ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 4; TUBULIN; ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; HDAC4 PROTEIN, HUMAN; REPRESSOR PROTEIN; SMO PROTEIN, MOUSE;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; CELL GROWTH; CEREBELLUM TUMOR; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CURCUMIN; HISTONE DEACETYLASES; HUMANS; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; RECEPTORS, G-PROTEIN-COUPLED; REPRESSOR PROTEINS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955117246     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-144     Document Type: Article

References (54)

1. Packer RJ. Childhood Brain Tumors: Accomplishments and Ongoing Challenges. J Child Neurol 2008, 23(10):1122-1127. 10.1177/0883073808320758, 18952578.
2. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol 2008, 3:341-365. 10.1146/annurev.pathmechdis.3.121806.151518, 18039127.
3. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy. Cancer Treatment Reviews 2009, 35(1):79-96. 10.1016/j.ctrv.2008.09.002, 18976866.
4. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008, 14(2):123-134. 10.1016/j.ccr.2008.07.005, 2597270, 18691547.
5. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004, 6(3):229-240. 10.1016/j.ccr.2004.08.019, 15380514.
6. Kimura H, Ng JMY, Curran T. Transient Inhibition of the Hedgehog Pathway in Young Mice Causes Permanent Defects in Bone Structure. Cancer Cell 2008, 13(3):249-260. 10.1016/j.ccr.2008.01.027, 18328428.
7. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267(1):133-164. 10.1016/j.canlet.2008.03.025, 18462866.
8. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269(2):199-225. 10.1016/j.canlet.2008.03.009, 18479807.
9. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21(21):8370-8377.
10. Perry MC, Demeule M, Regina A, Moumdjian R, Beliveau R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 2010, 54(8):1192-201.
11. Purkayastha S, Berliner A, Fernando SS, Ranasinghe B, Ray I, Tariq H, Banerjee P. Curcumin Blocks Brain Tumor Formation. Brain Res 2009,
12. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007, 13(6):1663-1674. 10.1158/1078-0432.CCR-06-2854, 17363519.
13. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57(2):178-201. 10.1016/j.neuron.2008.01.003, 18215617.
14. Fruhwald MC, Witt O. The epigenetics of cancer in children. Klin Padiatr 2008, 220(6):333-341. 10.1055/s-0028-1086026, 18949667.
15. Iacobuzio-Donahue CA. Epigenetic Changes in Cancer. Annual Review of Pathology: Mechanisms of Disease 2009, 4(1):229-249.
16. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23. 10.1016/j.gene.2005.09.010, 16289629.
17. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41(1):185-198. 10.1016/j.biocel.2008.08.027, 18804549.
18. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10(1):32-42. 10.1038/nrg2485, 19065135.
19. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(9):769-784. 10.1038/nrd2133, 16955068.
20. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS. Annual Review of Pharmacology and Toxicology 2005, 45(1):495-528. 10.1146/annurev.pharmtox.45.120403.095825, 15822187.
21. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6(1):38-51. 10.1038/nrc1779, 16397526.
22. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008, 15(5):237-243. 2582508, 19008999.
23. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003, 23(28):9418-9427.
24. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003, 100(4):2041-2046. 10.1073/pnas.0437870100, 149955, 12576549.
25. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413(6857):739-743. 10.1038/35099568, 11607033.
26. Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, Olson EN, D'Mello SR. Neuroprotection by histone deacetylase-related protein. Mol Cell Biol 2006, 26(9):3550-3564. 10.1128/MCB.26.9.3550-3564.2006, 1447420, 16611996.
27. Salminen A, Tapiola T, Korhonen P, Suuronen T. Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res Mol Brain Res 1998, 61(1-2):203-206. 10.1016/S0169-328X(98)00210-1, 9795219.
28. Boutillier AL, Trinh E, Loeffler JP. Constitutive repression of E2F1 transcriptional activity through HDAC proteins is essential for neuronal survival. Ann N Y Acad Sci 2002, 973:438-442. 10.1111/j.1749-6632.2002.tb04679.x, 12485907.
29. Boutillier AL, Trinh E, Loeffler JP. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 2003, 84(4):814-828. 10.1046/j.1471-4159.2003.01581.x, 12562525.
30. Morrison BE, Majdzadeh N, D'Mello SR. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 2007, 64(17):2258-2269. 10.1007/s00018-007-7035-9, 17530170.
31. Bangaru ML, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res 2010, 30(2):499-504.
32. Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y, Al-Kofide A, Aboussekhra A. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog 2010, 49(3):302-314.
33. Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, Ryazantsev S, Sakamoto K, Weinstein J, Rao NP, Rajasekaran AK. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther 2008, 7(7):2142-2151. 10.1158/1535-7163.MCT-08-0005, 2548318, 18645024.
34. Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 2008, 68(6):1768-1776. 10.1158/0008-5472.CAN-07-5092, 18339857.
35. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005, 70(5):700-713. 10.1016/j.bcp.2005.04.043, 16023083.
36. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007, 6(2):178-184. 10.4161/cbt.6.2.3577, 1852522, 17218783.
37. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005, 8(1):7-12. 10.1016/j.ccr.2005.06.011, 16023594.
38. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004, 7(5):637-651. 10.1016/j.devcel.2004.09.002, 15525526.
39. Gupta KK, Bharne SS, Rathinasamy K, Naik NR, Panda D. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J 2006, 273(23):5320-5332. 10.1111/j.1742-4658.2006.05525.x, 17069615.
40. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009, 8(8):2086-2095. 10.1158/1535-7163.MCT-09-0366, 19671735.
41. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003, 4(12):938-947. 10.1038/nrm1260, 14685172.
42. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1(3):194-202. 10.1038/35106079, 11902574.
43. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 2008, 68(8):1076-1092. 10.1002/dneu.20637, 2722383, 18498087.
44. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004, 279(49):51163-51171. 10.1074/jbc.M409024200, 15383533.
45. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008, 118(3):868-878. 2248328, 18292809.
46. Martin M, Kettmann R, Dequiedt F. Class IIa histone deacetylases: regulating the regulators. Oncogene 2007, 26(37):5450-5467. 10.1038/sj.onc.1210613, 17694086.
47. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol 2010, 12(2):132-142. 10.1038/ncb2013, 20081843.
48. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361(12):1173-1178. 10.1056/NEJMoa0902903, 19726761.
49. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326(5952):572-574. 10.1126/science.1179386, 19726788.
50. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008, 10(3):511-545. 10.1089/ars.2007.1769, 18370854.
51. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10(20):6847-6854. 10.1158/1078-0432.CCR-04-0744, 15501961.
52. Lee DS, Lee MK, Kim JH. Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res 2009, 29(12):5039-5044.
53. Freudlsperger C, Greten J, Schumacher U. Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB. Anticancer Res 2008, 28(1A):209-214.
54. Hussain AR, Al-Rasheed M, Manogaran PS, Al-Hussein KA, Platanias LC, Al Kuraya K, Uddin S. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006, 11(2):245-254. 10.1007/s10495-006-3392-3, 16502262.